COMMUNIQUÉS West-GlobeNewswire

CHMP recommends RYBREVANT®▼ (amivantamab) in combination with chemotherapy for the treatment of adult patients with advanced EGFR-mutated non-small cell lung cancer (NSCLC) after failure of prior therapy
26/07/2024
Patients with EGFR ex19del or EGFR L858R mutations, the most common EGFR mutations in NSCLC, currently face a poor prognosis and limited treatment options after disease progression on osimertinib 1 ,2,3,4 In the [...]
TRxADE Health, Inc. Announces Business Combination with Scienture, Inc., in a Transaction Valued at $103 Million
26/07/2024
Scienture, Inc., a private branded and specialty pharmaceutical company, entered into a business combination with TRxADE Health Inc., in an all-stock transaction valued at $103 million. TAMPA, FL and COMMACK, NY, July [...]
Krystal Biotech to Report Second Quarter 2024 Financial Results on August 5, 2024
26/07/2024
PITTSBURGH, July 26, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that it will report its second quarter 2024 financial results [...]
Predictive Oncology Announces Exercise of Warrants for $1.26 Million Gross Proceeds
26/07/2024
PITTSBURGH, July 26, 2024 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery and biologics, today announced that it has entered into a definitive agreement for the exercise [...]
Genetic Technologies Strategic Restructure Driving USA Sales Growth
26/07/2024
CHARLOTTE, N.C., July 26, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GENE”), a global leader in genomics-based tests in health, wellness and serious disease and the parent [...]
GENFIT: Positive Opinion from EMA Committee for Ipsen’s Iqirvo® (elafibranor) in Primary Biliary Cholangitis
26/07/2024
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), July 26, 2024 - GENFIT (Nasdaq and Euronext: GNFT) , a late-stage biopharmaceutical company dedicated to improving the lives of patients [...]
GENFIT : Avis positif du Comité des médicaments à usage humain (CHMP) pour l’Iqirvo® (élafibranor) d’Ipsen dans la Cholangite Biliaire Primitive
26/07/2024
Lille (France), Cambridge (Massachusetts, États-Unis), Zurich (Suisse), 26 juillet 2024 - GENFIT (Nasdaq et Euronext : GNFT) , une société biopharmaceutique de stade clinique avancé engagée dans l’amélioration de la vie [...]
Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union
26/07/2024
TOKYO and CAMBRIDGE, Mass., July 26, 2024 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: [...]
Johnson & Johnson Receives Positive CHMP Opinion for Yuvanci® (Single Tablet Combination Therapy [STCT] of Macitentan and Tadalafil) for Treatment of Patients with Pulmonary Arterial Hypertension (PAH)
26/07/2024
If approved, Yuvanci ® would become the only single tablet combination for treatment for patients with PAH Johnson & Johnson’s comprehensive PAH portfolio has the potential to cover all guideline-recommended [...]
Chemomab Therapeutics Regains Compliance With Nasdaq Minimum Bid Price Requirement
26/07/2024
TEL AVIV, Israel, July 26, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab) a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with [...]
Legend Biotech Announces Preliminary Results for the Six-Months Ended June 30, 2024
26/07/2024
SOMERSET, N.J., July 26, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced preliminary, unaudited financial results for the six-months [...]
Ipsen receives CHMP positive opinions for Iqirvo® (elafibranor) in Primary Biliary Cholangitis and Kayfanda® (odevixibat) in Alagille Syndrome, two rare cholestatic liver diseases
26/07/2024
Ipsen receives CHMP positive opinions for Iqirvo ® (elafibranor) in Primary Biliary Cholangitis and Kayfanda ® (odevixibat) in Alagille Syndrome, two rare cholestatic liver diseases CHMP positive opinion for Iqirvo ® ( [...]
Ipsen reçoit des avis positifs du CHMP pour Iqirvo® (elafibranor) dans la cholangite biliaire primitive et Kayfanda® (odévixibat) dans le syndrome d'Alagille, deux maladies rares du foie cholestatiques
26/07/2024
Le CHMP a émis un avis positif concernant Iqirvo ® (elafibranor) pour le traitement de la cholangite biliaire primitive, à la suite de l’approbation de la FDA en juin 2024. Le CHMP a émis un avis positif concernant [...]
Bavarian Nordic Receives Positive CHMP Opinion for Including Mpox Real-world Effectiveness Data in European Marketing Authorization for Smallpox and Mpox Vaccine
26/07/2024
Real-world data demonstrating vaccine effectiveness against mpox of up to 90% after two MVA-BN doses and a significant reduction of the risk of mpox-related hospitalizations COPENHAGEN, Denmark, July 26, 2024 – Bavarian [...]
Kaerus Bioscience annonce le lancement de l’essai clinique de phase I ciblé sur son nouveau modulateur de canal BK KER-0193 en cours de développement pour le syndrome de l’X fragile
26/07/2024
LONDRES, 26 juill. 2024 (GLOBE NEWSWIRE) -- Kaerus Bioscience Ltd. ( www.kaerusbio.com ), une société de biotechnologie au stade clinique axée sur le développement de traitements pour les syndromes génétiques rares [...]
California Institute for Regenerative Medicine Awards Funding for CAR-T NXC-201 U.S. AL Amyloidosis Clinical Trial (NEXICART-2)
26/07/2024
$8 million grant funds development of NXC-201 in relapsed/refractory AL Amyloidosis LOS ANGELES, CA, July 25, 2024 (GLOBE NEWSWIRE) -- Nexcella, Inc. (“Nexcella”, “Company”, “We” or “Us”), a clinical-stage [...]
California Institute for Regenerative Medicine Awards Funding for CAR-T NXC-201 U.S. AL Amyloidosis Clinical Trial (NEXICART-2)
26/07/2024
$8 million grant funds development of NXC-201 in relapsed/refractory AL Amyloidosis LOS ANGELES, CA, July 25, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us”, “IMMX”) (Nasdaq: IMMX), [...]
OnKure Announces the Appointment of Dylan Hartley as Chief Scientific Officer
26/07/2024
BOULDER, Colo., July 25, 2024 (GLOBE NEWSWIRE) -- OnKure, Inc. today announced that Dylan Hartley, Ph.D. has been appointed to the position of Chief Scientific Officer. In this position, Dr. Hartley will lead the [...]
BioAtla Highlighted Clinical Program and Pipeline Updates at Virtual R&D Day
25/07/2024
Clinical benefit observed among non-small cell lung cancer (NSCLC) patients harboring mutant KRAS (mKRAS) variants in the Phase 2 mecbotamab vedotin (CAB-AXL-ADC) study; AXL tumoral expression highly associated with [...]

Pages